RxDoctor Payments Data

Rudolfo Panganiban, MD

Pain Medicine · New Port Richey, FLNPI 1982671392

Payments from drug & device makers

$2,027in general payments, 2019–2025

Across 134 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zyla Life Sciences, Inc.$359
  • AbbVie$353
  • Collegium Pharmaceutical, Inc.$211
  • Biodelivery Sciences International, Inc.$211
  • Boston Scientific$171
  • Lundbeck LLC$145
  • plus $576 from 11 others

What the payments were for

  • Food & beverage$2,027100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,027 in reported general payments places this provider in the 45th percentile of 596 pain medicine providers in Florida.

See all pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$158,000
Medicare patients
211
Services billed
3,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate210$119,359
NucyntaTapentadol Hcl35$46,725
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,246$37,345
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen907$34,664
Fentanyl190$33,981
Nucynta ErTapentadol Hcl34$33,833
OxycontinOxycodone Hcl29$31,281
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl112$22,488
Oxycodone Hcl715$17,670
Morphine Sulfate ErMorphine Sulfate538$17,650
Pregabalin251$16,290
Hysingla ErHydrocodone Bitartrate21$14,783
Tramadol Hcl ErTramadol Hcl217$11,537
SuboxoneBuprenorphine Hcl/Naloxone Hcl22$11,257
MovantikNaloxegol Oxalate22$9,245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta, Nucynta Er$211$199,917279 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 596 pain medicine providers in Florida.

Other pain medicine in New Port Richey

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →